Figure 5.
Figure 5. Effect of the PKC inhibitor, bisindolylmaleimide, and the p38 MAPK inhibitor, SB203580, on HOCl-LDL-induced aggregation. The effect of bisindolylmaleimide is shown in panel A and SB203580 is shown in panel B. ADP (10 μM); bisindolylmaleimide (PKCI, 3 μg/mL) + ADP (10 μM); HOCl-LDL alone (20 μg/mL); bisindolylmaleimide (3 μg/mL) + HOCl-LDL alone (20 μg/mL); HOCl-LDL (20 μg/mL) + 1 μM ADP; (f) HOCl-LDL (20 μg/mL) + 1 μM ADP + bisindolylmaleimide (3 μg/mL).

Effect of the PKC inhibitor, bisindolylmaleimide, and the p38 MAPK inhibitor, SB203580, on HOCl-LDL-induced aggregation. The effect of bisindolylmaleimide is shown in panel A and SB203580 is shown in panel B. ADP (10 μM); bisindolylmaleimide (PKCI, 3 μg/mL) + ADP (10 μM); HOCl-LDL alone (20 μg/mL); bisindolylmaleimide (3 μg/mL) + HOCl-LDL alone (20 μg/mL); HOCl-LDL (20 μg/mL) + 1 μM ADP; (f) HOCl-LDL (20 μg/mL) + 1 μM ADP + bisindolylmaleimide (3 μg/mL).

Close Modal

or Create an Account

Close Modal
Close Modal